1522 - MAVRiC: A Phase 2 Study of Mutation-Guided Finite-Duration Acalabrutinib Plus Venetoclax for Relapse After Frontline Finite-Duration Covalent Bruton Tyrosine Kinase Inhibitor Plus Venetoclax‒Based Combination Therapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Primary Author / Presenter(s)

Matthew S. Davids, MD, MMSc

Director, Clinical Research, Division of Lymphoma; Associate Professor of Medicine
Dana-Farber Cancer Institute
Boston, Massachusetts, United States